Skip to content
value.today
Cleveland Biolabs Inc. logo

Cleveland Biolabs Inc.

Total raised
$36 M
5 rounds on record
Latest round
$2 M
Jun 2020
First round on record
Mar 2010
Today
Private
See the company page

Cleveland Biolabs Inc. is listed today as Cleveland BioLabs: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cleveland Biolabs Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$2 MNo. 5Under $2 million

Cleveland Biolabs Inc.: Raise no. 5, Jun 2020

Investors in this round

3 investors had bought by the notice of Jun 4, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$230,188
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrei S. Gudkov, Ph.D., D., Sci. · Executive Officer
  • Christopher Zosh · Executive Officer
  • Langdon S. Miller, MD · Executive Officer
  • Alexander S. Andryushechkin · Director
  • Anna S. Evdokimova · Director
  • Daniil S. Talyanskiy · Director
  • Ivan S. Fedyunin · Director
  • Lea S. Verny · Director
  • Randy S. Saluck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, IL, NY

Remarks in the notice

  • On fees: “In connection with a registered direct offering made concurrently with this placement, the issuer paid approximately $230,188 in placement agent fees and certain other compensation, as previously disclosed.”
  • On the amounts: “The offering amount includes the aggregate purchase and exercise price of the warrants.”

Signed by Christopher Zosh, Vice President of Finance. Source: SEC Form D, newest notice filed Jun 4, 2020. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$1 MNo. 4Under $2 million

Cleveland Biolabs Inc.: Raise no. 4, Dec 2015

Investors in this round

1 investor had bought by the notice of Dec 23, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrei J Gudkov · Executive Officer, Director
  • C Neil Lyons · Executive Officer
  • Langdon Neil Miller · Executive Officer
  • Yakov J Kogan · Executive Officer, Director
  • Anna Neil Evdokimova · Director
  • Anthony J Principi · Director
  • Ivan Neil Persiyanov · Director
  • James J Antal · Director
  • Konstantin Neil Gorshkov · Director
  • Natalia Neil Khudyk · Director
  • Natalia Neil Saraeva · Director
  • Randy S Saluck · Director
  • Richard S McGowan · Director
  • Tatiana Neil Levina · Director
  • Yulia Neil Lebedina · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Neil Lyons, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 23, 2015. Read the notice at the SEC.

equitySEC
Jul 2015$25 MNo. 3$10 to $50 million

Cleveland Biolabs Inc.: Raise no. 3, Jul 2015

Investors in this round

1 investor had bought by the notice of Jul 16, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$685,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrei J. Gudkov · Executive Officer, Director
  • C. Neil Lyons · Executive Officer
  • Yakov J. Kogan · Executive Officer, Director
  • Anna Neil Evdokimova · Director
  • Anthony J. Principi · Director
  • Ivan Neil Persiyanov · Director
  • James J. Antal · Director
  • Konstantinie Neil Gorshkov · Director
  • Natalia Neil Khudyk · Director
  • Natalia Neil Saraeva · Director
  • Randy S. Saluck · Director
  • Richard S. McGowan · Director
  • Tatiana Neil Levina · Director
  • Yulia Neil Lebedina · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg & Thalmann & Co., Inc. (CRD 505) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “See the Company's Current Report on Form 8-K filed with the SEC on July 10, 2015.”

Signed by C. Neil Lyons, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 16, 2015. Read the notice at the SEC.

equitySEC
Jun 2014$4 MNo. 2$2 to $10 million

Cleveland Biolabs Inc.: Raise no. 2, Jun 2014

Investors in this round

3 investors had bought by the notice of Jul 3, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$30,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrei R. Gudkov · Executive Officer, Director
  • C. Neil Lyons · Executive Officer
  • Alexander R. Polinsky · Director
  • Anthony J. Principi · Director
  • Daniel F. Hoth · Director
  • James R. Antal · Director
  • Julia R. Brown · Director
  • Randy S. Saluck · Director
  • Richard S. McGowan · Director
  • Yakov F. Kogan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C.WAINWRIGHT & CO., LLC (CRD 375) · New York, New YorkSold in all US states

Signed by Neil Lyons, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 3, 2014. Read the notice at the SEC.

equity, optionsSEC
Mar 2010$5 MNo. 1$2 to $10 million

Cleveland Biolabs Inc.: Raise no. 1, Mar 2010

Investors in this round

9 investors had bought by the notice of Mar 5, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$350,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrei Gudkov · Director, Executive Officer
  • Jack Marhofer · Executive Officer
  • Michael Fonstein · Director, Executive Officer
  • Yakov Kogan · Director, Executive Officer
  • Bernard L. Kasten · Director
  • Daniel Perez · Director
  • James Antal · Director
  • Paul DiCorleto · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · broker-dealer Rodman & Renshaw, LLC (CRD 16415) · New York, NySold in no state named

Remarks in the notice

  • On fees: “Rodman and Renshaw received approximately $350,000 in cash and Warrants to purchase 123,077 shares of Cleveland Biolabs, Inc. common stock at an exercise price of $4.50 per share.”

Signed by Michael Fonstein, President and CEO. Source: SEC Form D, newest notice filed Mar 5, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cleveland Biolabs Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

That is all the official record says: Cleveland Biolabs Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cleveland Biolabs Inc. are on record.

Investors#

No investor of Cleveland Biolabs Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cleveland Biolabs Inc.
NameRoleNamed in
Andrei S. Gudkov, Ph.D., D., Sci.Executive officerJun 2020
Christopher ZoshExecutive officerJun 2020
Langdon S. Miller, MDExecutive officerJun 2020
Andrei J GudkovExecutive officerDec 2015
C Neil LyonsExecutive officerDec 2015
Langdon Neil MillerExecutive officerDec 2015
Yakov J KoganExecutive officerDec 2015
Andrei J. GudkovExecutive officerJul 2015
C. Neil LyonsExecutive officerJul 2015
Yakov J. KoganExecutive officerJul 2015
Andrei R. GudkovExecutive officerJul 2014
Andrei GudkovExecutive officerMar 2010
Jack MarhoferExecutive officerMar 2010
Michael FonsteinExecutive officerMar 2010
Yakov KoganExecutive officerMar 2010
Alexander S. AndryushechkinDirectorJun 2020
Anna S. EvdokimovaDirectorJun 2020
Daniil S. TalyanskiyDirectorJun 2020
Ivan S. FedyuninDirectorJun 2020
Lea S. VernyDirectorJun 2020
Randy S. SaluckDirectorJun 2020
Andrei J GudkovDirectorDec 2015
Anna Neil EvdokimovaDirectorDec 2015
Anthony J PrincipiDirectorDec 2015
Ivan Neil PersiyanovDirectorDec 2015
James J AntalDirectorDec 2015
Konstantin Neil GorshkovDirectorDec 2015
Natalia Neil KhudykDirectorDec 2015
Natalia Neil SaraevaDirectorDec 2015
Randy S SaluckDirectorDec 2015
Richard S McGowanDirectorDec 2015
Tatiana Neil LevinaDirectorDec 2015
Yakov J KoganDirectorDec 2015
Yulia Neil LebedinaDirectorDec 2015
Andrei J. GudkovDirectorJul 2015
Anthony J. PrincipiDirectorJul 2015
James J. AntalDirectorJul 2015
Konstantinie Neil GorshkovDirectorJul 2015
Richard S. McGowanDirectorJul 2015
Yakov J. KoganDirectorJul 2015

About

Biotech company based in Buffalo, USA.